NCT03060343Unknown早期 1 期
Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting PD-L1 and CD80/CD86 (Zeushield Cytotoxic T Lymphocytes) for the Treatment of Recurrent or Refractory Non Small Cell Lung Cancer
Yu Fenglei1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2016年11月28日最近更新:
适应症
试验速览
- 阶段
- 早期 1 期
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
研究概览
简要总结
A single-center, open-label pilot study to determine the safety, tolerance and engraftment potential of zeushield cytotoxic T lymphocytes in subjects with PD-L1+ positive non-small cell lung cancer.
详细描述
The purpose of this first in human study is to determine the safety and feasibility of Zeushield Cytotoxic T Lymphocytes(Z-CTLs) in patients with relapsed or refractory NSCLC. Z-CTLs therapy is a novel immunotherapy under investigation in which patients have their T-cells (a type of white blood cell) collected and modified in the laboratory, before they are given back to the patient. The T-cells are modified to transform the intracellular signal domain of PD-1 and CTLA-4 to immune activation stimulus signal and transform T cells to a new kind of cancer-killer cells: zeushield cytotoxic T lymphocytes (Z-CTls).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women aged >18 years old
- •Subjects are diagnosed as refractory, recurrent ,metastatic, advanced non-small cell lung cancer by histological and cytological methods including specific lesion-targeted brush biopsy, lavage and fine needle aspiration;
- •Have at least one new measurable tumor lesion compared with previous irradiated region
- •Tumor tissues samples confirmed as PD-L1 positive
- •Expected survival≥12 weeks
- •ECOG scored as 0-1 or KPS grading > 80
- •PLT≥100000/mm3
- •Hb≥9.0g/dL
- •Serum creatinine≤2.5mg/dL，CCR≥50ml/min (renal malfunction defined as CCR<50ml/min according to Cockroft-Gault formula)
- •ALT and AST≤2.5ULN; for liver metastasis，ALT and AST ≤5ULN
- •Serum TBiL≤3.0mg/dL, TBiL≤2.5ULN
- •PT: INR < 1.7 or extended PT to normal value < 4s
- •Adequate venous access for apheresis or venous blood collection, and no other contraindication of blood cell separation
- •Patients with willingness to be in this study and able to provide informed consent
- •Capable of receiving treatment and follow up, included subjects are required to receive treatment in the enrolled centre
- •Women of childbearing age are required to take acceptable measures to minimize the possibility of pregnancy during whole session. Women of childbearing age must have negative results of serum or urine tests within 24 hours prior to infusion. Women subjects must not be in lactation;
排除标准
- •pregnant women or women in lactation
- •active HBV or HCV infection
- •HIV/AIDS infection
- •active infection
- •previously suffered from diseases or concurrent diseases as followed：
- •patients confirmed as severe autoimmune diseases in long-term (over 2 months) need of systemic immune inhibitors (steroid) or as immune-mediated symptomatic diseases including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune vasculitis (for example, Wegener's granulomatosis)
- •subjects with previous diagnosis as motor neurone disease caused by autoimmunity
- •subjects previously suffered from toxic epidermal necrolysis (TEN)
- •subjects with any mental diseases including dementia, mental status change that may impinge the understanding and performance of informed consent and related questionnaire
- •subjects with severe, uncontrollable diseases judged by investigators that may hinder them receiving this treatment
- •subjects with previously active malignant tumors including basal or squamous skin cancer, superficial bladder cancer, and in situ breast carcinoma within 5 years who had been completely cured without the need of follow-up treatment are not excluded.
- •during ongoing treatment using systemic steroid or steroid inhalants
- •subjects with unstable or active peptic ulcer or alimentary tract hemorrhage
- •subjects with previous organ transplantation or ready for organ transplantation
- •subjects in need of anticoagulant therapy treatment (warfarin or heparin)
- •subjects judged by investigators as not appropriate for this study
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
时间窗: 8 weeks
Observe and determine the potential adverse events related to the escalating dose infusion of Z-CTLs such as high fever,jaundice, kidney failure and so on.
次要结局
- Number of Z-CTLs in peripheral blood samples after infusion(8 weeks)
- Objective response rate (ORR)(2 years)
- Progression free survival (PFS)(2 years)
- Time to tumor progression (TTP)(2 years)
- Overall survival (OS)(2 years)
研究者
Yu Fenglei
Chief of the Thoracic Surgery Department
Second Xiangya Hospital of Central South University
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic AdenocarcinomaAdvanced Gastric AdenocarcinomaPancreatic AdenocarcinomaNCT03159819Changhai Hospital24
Unknown
1 期
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell CarcinomaLung Squamous Cell CarcinomaNCT02876978CARsgen Therapeutics Co., Ltd.20
已完成
1 期
CART-BCMA Cells for Multiple MyelomaMultiple MyelomaNCT02546167University of Pennsylvania25
Unknown
不适用
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsB Cell LymphomaB Cell LeukemiaMyelomaPancreatic CarcinomaAdenocarcinoma of Esophagogastric JunctionHepatocellular CarcinomaNCT03302403Kang YU18
Unknown
1 期
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaRefractory or Relapsed Multiple MyelomaNCT03716856First Affiliated Hospital of Zhejiang University11